AI in Pharma: Insights from GlobalLink NEXT London 2025

We recently attended an exclusive event in London hosted by TransPerfect, focused on exploring the benefits and challenges of content localization. The event brought together industry leaders, localization specialists, and technology experts to discuss the future of multilingual content management – many of whom, including us, represented the pharmaceutical sector.

From an Amiculum perspective, we were particularly interested to hear more about how the multilingual content industry has successfully integrated AI into large-scale workflows. It was fascinating to see how these innovations have driven significant efficiency gains without compromising quality or compliance, especially in a traditionally conservative industry that has only recently begun to experience real disruption.

The event featured a diverse range of speakers, including academics, AI specialists, pharma content directors, technical experts and change management professionals.

Here are our key takeaways from this highly valuable event.

AI is being successfully integrated into pharmaceutical localization workflow

• AI is streamlining and enhancing key processes involved in content localization. This includes generation of plain language summaries of clinical trial documents, transformation of content to ensure patient accessibility and tailoring of outputs to align with company-specific templates.
• These advancements significantly reduce manual effort, improve efficiency in document processing and communication, and often deliver substantial cost savings, sometimes amounting to millions, while enabling major reductions in content development and localization timelines. They can also improve the speed of delivery of resources to those who really need them, including patients.

Human input is essential to validate outputs

• Human input remains essential for validating AI-generated content. Whether the process relates to content or linguistics, review, update and approval by a human expert is essential to ensure accuracy, consistency and compliance. 
• In multilingual events and interpretation, a balance is maintained between AI-driven solutions for speed and scale and human interpreters for nuance and trust.

The future will offer a range of further developments

• AI technology is advancing rapidly in many areas of pharma, including content localization. There are a number of related emerging applications, such as AI visibility engines that provide insights into how large language models and generative AI tools scan, assimilate, and summarize data from websites and online sources. Additionally, advanced chatbots are being developed to capture and analyse patient queries and reported side effects across multiple languages, further enhancing engagement and pharmacovigilance.
• AI tools and platforms are expected to become increasingly sophisticated and interconnected, transforming not only pharma but also other industries dealing with large volumes of data and documentation.

There are still key challenges to overcome

• Ensuring the accuracy and reliability of AI-generated content is a key challenge, particularly in regulated industries like pharmaceuticals. Addressing issues such as incorrect or fabricated AI outputs is critical for efficiency and reliability but also for instilling trust.
• Implementing AI tools within complex workflows demands significant time and investment in both technology and human expertise. However, success hinges on the active engagement and alignment of a broad range of stakeholders, including senior leadership. Ensuring that everyone understands the value and potential impact of the initiative is essential for progress and maintaining that commitment throughout the process is critical to achieving successful implementation and realizing the full benefits.

Integration of AI has commercial implications

• AI integration can lead to significant cost savings by reducing manual labour, improving efficiency and enabling faster, more accurate information delivery.
• Enhanced HCP and patient engagement driven by efficient access to clear communication and reliable information, may enable increased access to innovative new medicines. Fast, efficient multilingual AI solutions also expand market reach and improve customer satisfaction.

The future of pharma and AI

• The future of pharmaceuticals with AI is characterized by greater automation, improved patient communication, and more data-driven decision-making.
• As AI technology matures, its applications will expand, driving further innovation and commercial growth in the pharmaceutical sector and beyond.

A big thank you to TransPerfect for hosting and inviting us to this insightful event. We're excited to see how AI continues to shape the future of pharma – driving smarter workflows, better communication and meaningful progress.